Fertility preservation neglected at most cancer centers

Share this article:

Infertility is consistently listed as one of the most distressing long-term side effects of cancer treatment for adolescents and young adults. Yet, the leading National Cancer Institute-designated comprehensive cancer centers—which should be leaders in fertility preservation—may not adequately help patients protect their fertility.

Most of these centers do not have policies or procedures that consistently identify which patients may be at risk for fertility loss, inform patients of this risk in a timely manner, or refer them to fertility specialists, the study found. At the time of the study, there were 39 comprehensive cancer centers that treated adults.

"It can be shocking for patients to find out their fertility was affected when there were potential options that exist that were not offered to them," said lead study author Marla Clayman, PhD, MPH, an assistant professor of medicine at Northwestern University Feinberg School of Medicine, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, both in Chicago, Illinois. The study was published in the Journal of the National Comprehensive Cancer Network (2013; 11:1504-1509).

"These are the centers that are at the vanguard of research and have the most people and financial resources," Clayman added. "This should be part of the exemplary cancer care patients get in these centers."

The study found that only four of the 33 comprehensive cancer centers surveyed had policies for consistent provision of fertility preservation information, though 20 sites had some services onsite and eight sites had referral programs. Only 13 had such experimental services as ovarian tissue cryopreservation; and only eight sites had staff time dedicated to fertility preservation.

Survival rates for young cancer patients have steadily increased over the past four decades due to more effective treatments. More women and men look forward to life after cancer, and having children is a key part of their hope for the future.

"When you think about having children after cancer, that's a very strong way to think about surviving and thriving after cancer," Clayman said. "It's not just that you want to live, it's that you want to live a life as close as possible that you could have without cancer."

Fertility navigators or a designated fertility educator are key to bridge the gap between oncology and fertility. But less than one-third of the centers had someone in this role, the study reported. The study concluded that, although comprehensive cancer centers are positioned to provide exemplary oncofertility care, most of them need to better integrate both information and referral about fertility preservation into their practices.

Fertility navigators or educators reduce the need for oncologists to have in-depth discussions about potential fertility loss and fertility preservation, a rapidly changing field in which they are not experts.

Clayman is a co-editor, along with Northwestern's Teresa Woodruff, PhD, and Kate Waimey, PhD, of the new book, Oncofertility Communication.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.